AMPK与心力衰竭发病机制和治疗的研究进展

心力衰竭（heart failure，HF）作为心血管疾病的终末阶段，是一种复杂的临床综合征，主要表现为心脏的收缩和舒张功能障碍。虽然治疗HF的药物在不断更新，但其病死率仍维持在较高水平，因此人们需要不断探索HF新的治疗靶点。近年来的研究表明单磷酸腺苷活化蛋白激酶（AMP-activated protein kinase，AMPK）参与HF的发生发展，可调控HF时的心肌代谢、心肌纤维化、氧化应激等。现对AMPK保护HF的机制及其相关药物的研究进展作一综述。

Research progress of AMPK and heart failure in pathogenesis and treatment

Heart failure (HF) is the final stage of cardiovascular disease and a complex clinical syndrome, which mainly manifested as systolic and diastolic dysfunction of the heart. Although the treatment of HF drugs are constantly updated, the fatality rate of it remains higher. Therefore, exploration of new therapeutic targets of HF is always in progress. Recent researches have shown that AMP-activated protein kinase (AMPK) is involved with the occurrence and development of HF. AMPK can regulate the myocardial metabolism, myocardial fibrosis and oxidative stress during the time of HF. In this review, we will discuss the mechanisms of AMPK in protecting HF and the progression of related drugs.